https://www.selleckchem.com/pr....oducts/avotaciclib-t
Inflation-adjusted cancer costs in the United States have increased 40% in the last decade, leading to increasing financial burden on both payers and patients. Patients under 65 show substantial increases in utilization of expensive targeted therapy anticancer agents; however, patients aged 65+ account for the majority of new malignancies. Utilization and cost trends for these emerging agents have not been examined in detail in the Medicare population. Retrospective prevalent cohort analysis of patients 65+ with any
Curtir
Comentario
Compartilhar
